Acasti Pharma (ACST) said Friday it will change its corporate name to Grace Therapeutics and begin trading on Nasdaq under its new ticker, "GRCE" on Oct. 28.
The name change reflects the company's origin and brand equity from Grace Therapeutics, which developed GTx-104 before merging with Acasti in 2021.
Acasti said it expects to release trial data for GTx-104, an injectable formulation targeting aneurysmal subarachnoid hemorrhage, in early 2025 aiming to submit a new drug application to the US Food and Drug Administration in H1 2025.
The company also said it has re-domiciled to the US as a Delaware corporation.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。